J Cancer 2020; 11(10):2769-2777. doi:10.7150/jca.38088

Research Paper

Impacts of RETN genetic polymorphism on breast cancer development

Chao-Qun Wang1,2, Chih-Hsin Tang3,4,5, Huey-En Tzeng6,7,8, Lulu Jin9, Jin Zhao9, Le Kang9, Yan Wang10, Gui-Nv Hu11, Bi-Fei Huang2, Xiaoni Li12, Yong-Ming Zhao11, Chen-Ming Su13✉, Hong-Chuan Jin1✉

1. Laboratory of Cancer Biology, Key Laboratory of Biotherapy in Zhejiang Province, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China
2. Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China
3. Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan
4. Chinese Medicine Research Center, China Medical University, Taichung, Taiwan
5. Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan
6. Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
7. Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
8. Division of Hematology/Oncology, Department of Medicine, Taipei Medical University-Shuang Ho Hospital, Taiwan
9. Department of Biomedical Sciences Laboratory, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China
10. Department of Medical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China
11. Department of Surgical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China
12. Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Anhui, China
13. Department of Sports Medicine, China Medical University, Taichung, Taiwan

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Wang CQ, Tang CH, Tzeng HE, Jin L, Zhao J, Kang L, Wang Y, Hu GN, Huang BF, Li X, Zhao YM, Su CM, Jin HC. Impacts of RETN genetic polymorphism on breast cancer development. J Cancer 2020; 11(10):2769-2777. doi:10.7150/jca.38088. Available from http://www.jcancer.org/v11p2769.htm

File import instruction

Abstract

The adipokine resistin is linked with obesity, inflammation and various cancers, including breast cancer. This study sought to determine whether certain polymorphisms in the gene encoding resistin, RETN, increase the risk of breast cancer susceptibility. We analyzed levels of resistin expression in breast cancer tissue and samples from The Cancer Genome Atlas database. We also examined associations between four RETN single nucleotide polymorphisms (SNPs; rs3745367, rs7408174, rs1862513 and rs3219175) and breast cancer susceptibility in 515 patients with breast cancer and 541 healthy women without cancer. Compared with wild-type (GG) carriers, those carrying the AG genotype of the RETN SNP rs3219175 and those carrying at least one A allele in the SNP rs3219175 had a higher chance of developing breast cancer (adjusted odds ratio, AOR: 1.295, 95% confidence intervals, CI: 1.065-1.575 and 2.202, 1.701-2.243, respectively). When clinical aspects and the RETN SNP rs7408174 were examined in the breast cancer cohort, the CT genotype was linked to late-stage disease, while women with luminal A disease and at least one C allele were likely to progress to stage III/IV disease and to develop highly pathological grade III disease. Moreover, resistin-positive individuals were at greater risk than resistin-negative individuals for developing pathological grade III disease (OR: 5.020; 95% CI: 1.380-18.259). This study details risk associations between resistin and RETN SNPs in breast cancer susceptibility in Chinese Han women.

Keywords: single nucleotide polymorphism, breast cancer, resistin, The Cancer Genome Atlas